Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Borderi

Showing results (21-30 of 67) with videos related to

Pageof 7
Sort By:
HIV Clinical Trials|May 18, 2018
Rosuvastatin and atorvastatin preserve renal function in HIV-1-infected patients with chronic kidney disease and hyperlipidaemiaLeonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
Infection|November 13, 2019
Weight gain in antiretroviral therapy-naive HIV-1-infected patients starting a regimen including an integrase strand transfer inhibitor or darunavir/ritonavirLeonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|May 10, 2013
HIV-related mechanisms in atherosclerosis and cardiovascular diseasesDavide Gibellini, Marco Borderi, Alberto Clò, et al.
AIDS (London, England)|January 7, 2017
Significant association between statin-associated myalgia and vitamin D deficiency among treated HIV-infected patientsLeonardo Calza, Eleonora Magistrelli, Vincenzo Colangeli, et al.
The Journal of Antimicrobial Chemotherapy|July 31, 2020
Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapyLeonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
Infectious Diseases (London, England)|September 21, 2020
Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in treated HIV-infected patients with metabolic syndromeLeonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
AIDS Research and Human Retroviruses|October 31, 2020
Short Communication: No Significant Changes in Weight and Body Fat Mass in Suppressed HIV-Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or RaltegravirLeonardo Calza, Marco Borderi, Vincenzo Colangeli, et al.
HIV Clinical Trials|May 18, 2012
Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-α in HIV-infected patients treated with ritonavir-boosted protease inhibitorsLeonardo Calza, Filippo Trapani, Michele Bartoletti, et al.
HIV Clinical Trials|April 20, 2017
Prevalence of metabolic syndrome in HIV-infected patients naive to antiretroviral therapy or receiving a first-line treatmentLeonardo Calza, Vincenzo Colangeli, Eleonora Magistrelli, et al.
Biochemical and Biophysical Research Communications|September 28, 2010
HIV-1 Tat protein enhances RANKL/M-CSF-mediated osteoclast differentiationDavide Gibellini, Elisa De Crignis, Cristina Ponti, et al.
Pageof 7

Showing results (21-30 of 67) with videos related to

Sort By:
Pageof 7
HIV Clinical Trials|May 18, 2018
Rosuvastatin and atorvastatin preserve renal function in HIV-1-infected patients with chronic kidney disease and hyperlipidaemiaLeonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
Infection|November 13, 2019
Weight gain in antiretroviral therapy-naive HIV-1-infected patients starting a regimen including an integrase strand transfer inhibitor or darunavir/ritonavirLeonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|May 10, 2013
HIV-related mechanisms in atherosclerosis and cardiovascular diseasesDavide Gibellini, Marco Borderi, Alberto Clò, et al.
AIDS (London, England)|January 7, 2017
Significant association between statin-associated myalgia and vitamin D deficiency among treated HIV-infected patientsLeonardo Calza, Eleonora Magistrelli, Vincenzo Colangeli, et al.
The Journal of Antimicrobial Chemotherapy|July 31, 2020
Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapyLeonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
Infectious Diseases (London, England)|September 21, 2020
Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in treated HIV-infected patients with metabolic syndromeLeonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
AIDS Research and Human Retroviruses|October 31, 2020
Short Communication: No Significant Changes in Weight and Body Fat Mass in Suppressed HIV-Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or RaltegravirLeonardo Calza, Marco Borderi, Vincenzo Colangeli, et al.
HIV Clinical Trials|May 18, 2012
Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-α in HIV-infected patients treated with ritonavir-boosted protease inhibitorsLeonardo Calza, Filippo Trapani, Michele Bartoletti, et al.
HIV Clinical Trials|April 20, 2017
Prevalence of metabolic syndrome in HIV-infected patients naive to antiretroviral therapy or receiving a first-line treatmentLeonardo Calza, Vincenzo Colangeli, Eleonora Magistrelli, et al.
Biochemical and Biophysical Research Communications|September 28, 2010
HIV-1 Tat protein enhances RANKL/M-CSF-mediated osteoclast differentiationDavide Gibellini, Elisa De Crignis, Cristina Ponti, et al.
Pageof 7